SHANGHAI PHARMACEUTICALS HOLDING CO., LTD

Shanghai Pharmaceuticals Holding Co., Ltd

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-01-13			5-day change	1st Jan Change
19.88 ^CNY	-0.15%		-2.93%	-5.33%

Jan. 02	Billionaire Li Ka-shing's Hutchmed in $608 million health unit stake sales	RE
Jan. 02	Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025	MT

Shanghai Pharma Gets Nod to Produce Apremilast Tablets

December 04, 2024 at 12:45 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Shanghai Pharmaceuticals Holding Co., Ltd

Billionaire Li Ka-shing's Hutchmed in $608 million health unit stake sales	Jan. 02	RE
Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025	Jan. 02	MT
HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million	Jan. 02	MT
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal	Jan. 01	MT
Hutchmed to Sell 45% Stake in JV for $608 Million	Jan. 01	MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Address of Principal Place of Business in Hong Kong, Effective January 10, 2025	Jan. 01	CI
Shanghai Pharmaceuticals Holding Co., Ltd agreed to acquire 10% stake in Shanghai Hutchison Pharmaceuticals Limited from Shanghai HUTCHMED Investment (HK) Limited for approximately CNY 1 billion.	Dec. 31	CI
Shanghai Pharmaceuticals Gets China Clinical Trial Nod for Schizophrenia Tablets	Dec. 19	MT
Shanghai Pharmaceuticals Gets Clinical Trial Approval for Varicose Vein Treatment	Dec. 11	MT
Shanghai Pharmaceuticals Gets US FDA Orphan Drug Designation for ALS Drug	Dec. 11	MT
Shanghai Pharmaceuticals Gets Marketing Authorization for Linarasen Glutarate Capsules	Dec. 04	MT
Shanghai Pharma Gets Nod to Produce Apremilast Tablets	Dec. 04	MT
Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results	Dec. 02	MT
Shanghai Pharmaceuticals Gets Clinical Trial Nod for Schizophrenia Tablets	Nov. 25	MT
Shanghai Pharmaceuticals' Pentoxifylline Passes Generic Drug Evaluation in China	Nov. 04	MT
Shanghai Pharmaceuticals' Ceftazidime Injection Passes Drug Consistency Evaluation	Nov. 01	MT
Shanghai Pharmaceuticals Report 6% Drop in Q3 Profit; Shares Slide 3%	24-10-30	MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-29	CI
Shanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol	24-10-07	MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-26	CI
Shanghai Pharmaceuticals Secures Approval for Production of Pain, Inflammation Capsule	24-08-06	MT
Shanghai Pharmaceuticals Unit's Methylcobalamin Tablets Passes Drug Regulator's Evaluation	24-08-06	MT
Shanghai Pharmaceuticals Gets Nod to Register Schizophrenia Drug	24-07-30	MT
Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration	24-07-24	MT
Shanghai Pharmaceuticals Unit's Anesthesia Passes Regulatory Evaluation	24-07-18	MT

Chart Shanghai Pharmaceuticals Holding Co., Ltd

Duration

Period

Chart Shanghai Pharmaceuticals Holding Co., Ltd

601607: Dynamic Chart

Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.

Employees

48,164

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company